Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2002 2
2003 2
2004 2
2005 4
2006 3
2007 1
2008 1
2009 3
2010 2
2012 1
2013 1
2014 2
2015 4
2016 2
2017 3
2018 1
2020 1
Text availability
Article attribute
Article type
Publication date

Search Results

34 results
Results by year
Filters applied: . Clear all
Page 1
Bacterial Factors That Predict Relapse after Tuberculosis Therapy.
Colangeli R, Jedrey H, Kim S, Connell R, Ma S, Chippada Venkata UD, Chakravorty S, Gupta A, Sizemore EE, Diem L, Sherman DR, Okwera A, Dietze R, Boom WH, Johnson JL, Mac Kenzie WR, Alland D; DMID 01-009/Tuberculosis Trials Consortium Study 22 Teams. Colangeli R, et al. N Engl J Med. 2018 Aug 30;379(9):823-833. doi: 10.1056/NEJMoa1715849. N Engl J Med. 2018. PMID: 30157391 Free PMC article. Clinical Trial.
Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortium.
Dorman SE, Goldberg S, Stout JE, Muzanyi G, Johnson JL, Weiner M, Bozeman L, Heilig CM, Feng PJ, Moro R, Narita M, Nahid P, Ray S, Bates E, Haile B, Nuermberger EL, Vernon A, Schluger NW; Tuberculosis Trials Consortium. Dorman SE, et al. J Infect Dis. 2012 Oct 1;206(7):1030-40. doi: 10.1093/infdis/jis461. Epub 2012 Jul 30. J Infect Dis. 2012. PMID: 22850121 Clinical Trial.
Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons.
Sterling TR, Scott NA, Miro JM, Calvet G, La Rosa A, Infante R, Chen MP, Benator DA, Gordin F, Benson CA, Chaisson RE, Villarino ME; Tuberculosis Trials Consortium, the AIDS Clinical Trials Group for the PREVENT TB Trial (TBTC Study 26ACTG 5259) The investigators of the TB Trials Consortium and the AIDS Clinical Trials Group for the PREVENT TB Trial are listed in the Supplement, item 17. Sterling TR, et al. AIDS. 2016 Jun 19;30(10):1607-15. doi: 10.1097/QAD.0000000000001098. AIDS. 2016. PMID: 27243774 Free PMC article. Clinical Trial.
The Tuberculosis Trials Consortium: a model for clinical trials collaborations.
Tuberculosis Trials Consortium, Division of TB Elimination, Centers for Disease Control and Prevention. Tuberculosis Trials Consortium, Division of TB Elimination, Centers for Disease Control and Prevention. Public Health Rep. 2001;116 Suppl 1(Suppl 1):41-9. doi: 10.1093/phr/116.s1.41. Public Health Rep. 2001. PMID: 11889274 Free PMC article. No abstract available.
Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid.
Villarino ME, Scott NA, Weis SE, Weiner M, Conde MB, Jones B, Nachman S, Oliveira R, Moro RN, Shang N, Goldberg SV, Sterling TR; International Maternal Pediatric and Adolescents AIDS Clinical Trials Group; Tuberculosis Trials Consortium. Villarino ME, et al. JAMA Pediatr. 2015 Mar;169(3):247-55. doi: 10.1001/jamapediatrics.2014.3158. JAMA Pediatr. 2015. PMID: 25580725 Free PMC article. Clinical Trial.
Population Pharmacokinetics of Pyrazinamide in Patients with Tuberculosis.
Alsultan A, Savic R, Dooley KE, Weiner M, Whitworth W, Mac Kenzie WR, Peloquin CA; Tuberculosis Trials Consortium. Alsultan A, et al. Antimicrob Agents Chemother. 2017 May 24;61(6):e02625-16. doi: 10.1128/AAC.02625-16. Print 2017 Jun. Antimicrob Agents Chemother. 2017. PMID: 28289033 Free PMC article.
Evaluation of Xpert MTB/RIF Versus AFB Smear and Culture to Identify Pulmonary Tuberculosis in Patients With Suspected Tuberculosis From Low and Higher Prevalence Settings.
Luetkemeyer AF, Firnhaber C, Kendall MA, Wu X, Mazurek GH, Benator DA, Arduino R, Fernandez M, Guy E, Johnson P, Metchock B, Sattler F, Telzak E, Wang YF, Weiner M, Swindells S, Sanne IM, Havlir DV, Grinsztejn B, Alland D; AIDS Clinical Trials Group A5295 and Tuberculosis Trials Consortium Study 34 Teams. Luetkemeyer AF, et al. Clin Infect Dis. 2016 May 1;62(9):1081-8. doi: 10.1093/cid/ciw035. Epub 2016 Feb 2. Clin Infect Dis. 2016. PMID: 26839383 Free PMC article.
Defining the optimal dose of rifapentine for pulmonary tuberculosis: Exposure-response relations from two phase II clinical trials.
Savic RM, Weiner M, MacKenzie WR, Engle M, Whitworth WC, Johnson JL, Nsubuga P, Nahid P, Nguyen NV, Peloquin CA, Dooley KE, Dorman SE; Tuberculosis Trials Consortium of the Centers for Disease Control and Prevention. Savic RM, et al. Version 2. Clin Pharmacol Ther. 2017 Aug;102(2):321-331. doi: 10.1002/cpt.634. Epub 2017 Mar 2. Clin Pharmacol Ther. 2017. PMID: 28124478 Free PMC article. Clinical Trial.
Impact of Larger Sputum Volume on Xpert® MTB/RIF Assay Detection of Mycobacterium tuberculosis in Smear-Negative Individuals with Suspected Tuberculosis.
Badal-Faesen S, Firnhaber C, Kendall MA, Wu X, Grinsztejn B, Escada RODS, Fernandez M, Hogg E, Sanne I, Johnson P, Alland D, Mazurek GH, Benator DA, Luetkemeyer AF; AIDS Clinical Trials Group A5295; Tuberculosis Trials Consortium Study 34 Teams. Badal-Faesen S, et al. J Clin Med. 2017 Aug 7;6(8):78. doi: 10.3390/jcm6080078. J Clin Med. 2017. PMID: 28783093 Free PMC article.
34 results
Jump to page
Feedback